ANTIVIRAL AND PHARMACOKINETIC PROPERTIES OF C2 SYMMETRICAL INHIBITORS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE

Specific processing of the human immunodeficiency virus (HIV) gag and gag-pol polyprotein gene products by the HIV protease is essential for the production of mature, infectious progeny virions. Inhibitors of HIV protease block this maturation and thus prohibit the spread of HIV in vitro. Previously, we reported a series of novel, symmetric inhibitors of HIV protease designed to match the C2 symmetric structure of the active site of the enzyme. In response to the poor aqueous solubility of those lead compounds, we designed a series of analogs with substantially improved (> 10(4)fold) solubility. These inhibitors showed anti-HIV activity in H9 and MT4 cells at 0.05 to 10-mu-M, and in most cases, they were noncytotoxic at concentrations in excess of 100-mu-M. Further examination of one inhibitor (A-77003) revealed broad-spectrum activity against both HIV types 1 and 2, including azidothymidine-resistant HIV, in a variety of transformed and primary human cell lines. After administration of the inhibitors to rats, short half-lives and, with two notable exceptions, moderate oral bioavailability were observed. Additional pharmacokinetic studies in dogs and monkeys revealed the potential utility of A-77003 as an intravenous anti-HIV agent.